Journal of hematology & oncology · 2025
B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escape.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Van der Vreken Arne, Meeus Fien, Tu Chenggong, van den Broecke Lauren, Raimondi Vincenzo, Vescovini Rosanna, Hanssens Heleen, Watté Fenja, Autaers Dorien, Aragon Marta Marco, Billiau Janne, De Veirman Kim, Vanderkerken Karin, De Vlaeminck Yannick, Franceschini Lorenzo, Lee Holly, Neri Paola, De Bruyne Elke, Storti Paola, Giuliani Nicola, Breckpot Karine, Menu Eline
Аннотация
BACKGROUND: CAR T cell therapy targeting BCMA has shown remarkable efficacy in multiple myeloma (MM), but relapses occur due to T cell exhaustion and the emergence of BCMA-negative subpopulations. Novel targets are needed to overcome antigen escape.
METHODS: B7-H3 (CD276) expression was assessed on primary MM patient samples. We engineered nanobody-based CAR T cells (nanoCARs) targeting B7-H3 and evaluated their cytotoxicity and cytokine production in vitro, including against patient-derived myeloma cells. Anti-tumor activity was tested in two different MM xenograft models. Dual CAR T cells (BCMA/B7-H3) and CARpooling (mix of BCMA and B7-H3 CAR T cells) were also tested for efficacy in antigen escape models.
RESULTS: B7-H3 expression was detected on plasma cells in 60% of MM patients. B7-H3 nanoCAR T cells exhibited strong antigen-specific cytotoxicity and effector cytokine secretion, including against primary MM cells. In vivo, they reduced tumor burden and improved survival. Dual (BCMA/B7-H3) CAR T cells and CARpooling effectively eliminated heterogeneous tumor populations with mutually exclusive BCMA or B7-H3 expression. These findings show that BCMA/B7-H3 targeting may be a strategy to overcome antigen escape mechanisms.
CONCLUSION: B7-H3 is a promising immunotherapy target in MM. B7-H3-specific and dual-targeting nanoCAR T cells could offer a strategy to prevent antigen escape and improve treatment durability.
METHODS: B7-H3 (CD276) expression was assessed on primary MM patient samples. We engineered nanobody-based CAR T cells (nanoCARs) targeting B7-H3 and evaluated their cytotoxicity and cytokine production in vitro, including against patient-derived myeloma cells. Anti-tumor activity was tested in two different MM xenograft models. Dual CAR T cells (BCMA/B7-H3) and CARpooling (mix of BCMA and B7-H3 CAR T cells) were also tested for efficacy in antigen escape models.
RESULTS: B7-H3 expression was detected on plasma cells in 60% of MM patients. B7-H3 nanoCAR T cells exhibited strong antigen-specific cytotoxicity and effector cytokine secretion, including against primary MM cells. In vivo, they reduced tumor burden and improved survival. Dual (BCMA/B7-H3) CAR T cells and CARpooling effectively eliminated heterogeneous tumor populations with mutually exclusive BCMA or B7-H3 expression. These findings show that BCMA/B7-H3 targeting may be a strategy to overcome antigen escape mechanisms.
CONCLUSION: B7-H3 is a promising immunotherapy target in MM. B7-H3-specific and dual-targeting nanoCAR T cells could offer a strategy to prevent antigen escape and improve treatment durability.